Skip to main content
Clinical Trials/NCT02572479
NCT02572479
Completed
Not Applicable

Observational Study for Evaluating the Potential of Diet and Food Components as Disease Modifiers in Amyotrophic Lateral Sclerosis (JERN_ALS)

University of Jena1 site in 1 country50 target enrollmentOctober 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Amyotrophic Lateral Sclerosis
Sponsor
University of Jena
Enrollment
50
Locations
1
Primary Endpoint
Clinical neurological examination
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients complemented by the analysis of fatty acid distribution in erythrocyte lipids. Both data sets are related to disease status and progress.

Detailed Description

Amyotrophic lateral sclerosis (ALS) is a currently incurable, multifactorial motor neuron disease characterized by upper and lower motor neuron degeneration, skeletal muscle atrophy, paralysis, and death. Multiple mechanisms caused by genetic and environmental factors proposed as responsible for ALS pathogenesis include decreased availability to neurotrophic factors, disturbances in calcium metabolism, increased neuroinflammatory status, cytoskeletal changes, mitochondrial dysfunction, dysfunction of protein degradation, glutamate excitotoxicity, apoptosis and oxidative stress. Currently, the only available drug to treat ALS is riluzole which slightly prolongs life. Nutritional management has become more important in the treatment of ALS because body mass index and nutritional status seems to be independent, prognostic factors for survival and disease complications. Malnutrition is common in ALS, so caloric supplementation is essential. Additionally, many ALS patients self-medicate with vitamins, herbs, and other dietary supplements. The objective of the current project is establishing the link between nutritional intake and disease status and progress. In detail, we like to assess if the improved outcomes are associated with specific nutrients, or simply the provision of excess calories. In this context, one of the most promising dietary candidates are polyunsaturated fatty acids (PUFA) and in particular the long-chain n-3 PUFA docosahexaenoic acid. This important structural component in neuronal membranes plays a role in neurogenesis and neuroprotection as well as exerts well-described anti-inflammatory effects in the brain. The proposed observational trial will collect substantial data concerning dietary intake documented by ALS patients (Food Frequency Protocols, FFPs, periodic over 5 days) combined with the analysis of fatty acid distribution in erythrocyte lipids which reflects fatty acid distribution of the consumed fatty or oily foods (time period: approximately the last 2-3 months). The fatty aids distribution in erythrocyte lipids as well as the nutrient intake calculated by FFPs are related to disease status and progress. Thus, the current research activities focus on identification of dietary factors that are associated with disease progress or survival to develop beneficial interventions and therapy options.

Registry
clinicaltrials.gov
Start Date
October 2015
End Date
October 2018
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University of Jena
Responsible Party
Principal Investigator
Principal Investigator

Christine Dawczynski,PhD

PhD

University of Jena

Eligibility Criteria

Inclusion Criteria

  • ALS patients diagnosed according to El Escorial / Awaji criteria for ALS
  • patients should have the ability to comprehend the full nature and purpose of the study, to cooperate with the investigator, to understand verbal and written instructions, and to comply with the requirements of the entire study.

Exclusion Criteria

  • patient's request or if patient compliance with the study protocol is doubtful

Outcomes

Primary Outcomes

Clinical neurological examination

Time Frame: through study completion, an average of 1 year

ALS functional rating scale-revised (ALSFRS-R) - the parameter will be assessed every three months through study completion

Secondary Outcomes

  • Fatty acid distribution in erythrocyte lipids(through study completion, an average of 1 year)
  • Nutrient intake by diet(through study completion, an average of 1 year)
  • Blood lipids(through study completion, an average of 1 year)
  • Inflammatory parameter(through study completion, an average of 1 year)
  • Metabolic serum parameters(through study completion, an average of 1 year)
  • Clinical neurological examination, part II(through study completion, an average of 1 year)

Study Sites (1)

Loading locations...

Similar Trials